North America Smoking Cessation Aids Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Product (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes, and Others) and End User (Hospital Pharmacies, Online Channel, Retail Pharmacies, and Other End Users)


No. of Pages: 115    |    Report Code: TIPRE00024112    |    Category: Life Sciences

North America Smoking Cessation Aids Market
Buy Now

 

 

Market Introduction

Smoking cessation lowers the risk of cancer and other serious health problems. Some products contain nicotine as an active ingredient and others do not. Counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, may be used to help a person quit smoking. They are regulated through the FDA’s Center for Drug Evaluation and Research, which ensures that the products are safe and effective and that their benefits outweigh any known associated risks.

 


Get more information on this report

North America Smoking Cessation Aids Strategic Insights

Strategic insights for the North America Smoking Cessation Aids provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-smoking-cessation-aids-market-strategic-framework.webp
Get more information on this report

North America Smoking Cessation Aids Report Scope

Report Attribute Details
Market size in 2021 US$ 9,049.15 Million
Market Size by 2028 US$ 25,126.27 Million
Global CAGR (2021 - 2028) 15.7%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product
  • Nicotine Replacement Therapy
  • Drugs
  • Electronic Cigarettes
By End User
  • Hospital Pharmacies
  • Online Channel
  • Retail Pharmacies
  • Other End Users
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Dr. Reddy's Laboratories
  • Johnson and Johnson Services, Inc.
  • Cipla Inc.
  • Perrigo Company plc
  • Bausch Health Companies Inc.
  • Glenmark
  • NJOY
  • Juul Labs
  • Get more information on this report

    North America Smoking Cessation Aids Regional Insights

    The geographic scope of the North America Smoking Cessation Aids refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/north-america-smoking-cessation-aids-market-geography.webp
    Get more information on this report


    Market Overview and Dynamics

    The North America smoking cessation aids market is expected to reach US$ 25,126.27 million in 2028 from US$ 9,049.15 million in 2021; it is estimated to grow at a CAGR of 15.7% from 2021 to 2028. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking and increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.

    The smoking of tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the World Health Organization (WHO), smoking-related disorders result in about 435,000 deaths per year in the US, which equals to around 1 in 5 of the total deaths in the country. Therefore, prevalence of tobacco smoking is high across various countries in the North America that drives the growth of the smoking cessation aids market. The government and nongovernment organizations worldwide are coming forward and launching campaigns to provide awareness and undertake measures to curb the diseases caused due to smoking and tobacco consumption. The measures are taken to reduce the economic and health burden caused due to cigarette smoking in countries worldwide. For instance, every year on May 31st, the WHO along with its global partners celebrate World No Tobacco Day (WNTD) to spread education and awareness regarding the harmful and deadly effects of tobacco and second-hand smoke exposure. Initiatives undertaken on this day mainly aim to discourage the consumption of tobacco in any form and educate people regarding the availability of aids that assist in smoking cessation. The launch of anti-smoking campaigns is organized on global, national, and regional levels worldwide.  The governments of various countries have increased excise duties and taxes on tobacco-based cigarettes and cigars to reduce its affordability, thus consumption among common populace. In addition, numerous governments have legalized the use of e-cigarettes as a smoking cessation aid under licensed sales channels to prevent people from opting conventional cigarettes. Thus, the increasing efforts undertaken by governments as well as non-profit and nongovernment organizations to promote the use of smoking cessation aids and reduce the number of smoking populations boost the growth of the market.

    The North American region is highly affected due to the outbreak of the COVID-19 pandemic. Researchers from Stanford University show that teenagers and young adults of age 13–24 years, who use e-cigarettes, are five times more inclined to be diagnosed with COVID-19 than their non-vaping peers. As per the WHO, they have been evaluating new research constantly, the new research states that there is positive relation between tobacco use, nicotine use helping COVID-19 patients to get well. For increasing risk for COVID-19, smoking is the major cause of underlying health conditions. However, there is currently insufficient information to confirm any link between tobacco or nicotine in the prevention or treatment of COVID-19. Hence, COVID-19 pandemic does not show significant impact on smoking cessation aids market.

     

    Key Market Segments

    Based on product, the North America smoking cessation aids market is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. In 2021, the electronic cigarettes segment is likely to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.

    Based on end user, the North America smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, whereas the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.

     

    Major Sources and Companies Listed

    A few of the primary and secondary sources associated with this report on the North America smoking cessation aids market are the United Nations Office of Drugs and Crime (UNODC), American Addictions Center (AAC), and United Nations Educational, Scientific and Cultural Organization (UNESCO).

     

    Reasons to buy the report

    • Determine prospective investment areas based on a detailed trend analysis of North America smoking cessation aids market over the next years.
    • Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
    • Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
    • Identify the major channels driving the North America smoking cessation aids market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
    • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America smoking cessation aids market.

     

    NORTH AMERICA SMOKING CESSATION AIDS MARKET SEGMENTATION

    By Product

    • Nicotine Replacement Therapy
    • Drugs
    • Electronic Cigarettes
    • Other End Users

     

    By End User

    • Hospital Pharmacies
    • Online Channel
    • Retail Pharmacies
    • Others

    By Country

    • US
    • Canada
    • Mexico

    Company Profiles

    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Dr. Reddy's Laboratories
    • Johnson and Johnson Services, Inc.
    • Cipla Inc.
    • Perrigo Company plc
    • Bausch Health Companies Inc.
    • Glenmark
    • NJOY
    • Juul Labs

     

     

     

     

    The List of Companies - North America Smoking Cessation Aids Market

    1. Pfizer Inc.
    2. GlaxoSmithKline plc.
    3. Dr. Reddy's Laboratories
    4. Johnson and Johnson Services, Inc.
    5. Cipla Inc.
    6. Perrigo Company plc
    7. Bausch Health Companies Inc.
    8. Glenmark
    9. NJOY
    10. Juul Labs
    11.  
    Frequently Asked Questions
    How big is the North America Smoking Cessation Aids Market?

    The North America Smoking Cessation Aids Market is valued at US$ 9,049.15 Million in 2021, it is projected to reach US$ 25,126.27 Million by 2028.

    What is the CAGR for North America Smoking Cessation Aids Market by (2021 - 2028)?

    As per our report North America Smoking Cessation Aids Market, the market size is valued at US$ 9,049.15 Million in 2021, projecting it to reach US$ 25,126.27 Million by 2028. This translates to a CAGR of approximately 15.7% during the forecast period.

    What segments are covered in this report?

    The North America Smoking Cessation Aids Market report typically cover these key segments-

    • Product (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes)
    • End User (Hospital Pharmacies, Online Channel, Retail Pharmacies, Other End Users)

    What is the historic period, base year, and forecast period taken for North America Smoking Cessation Aids Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Smoking Cessation Aids Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in North America Smoking Cessation Aids Market?

    The North America Smoking Cessation Aids Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Dr. Reddy's Laboratories
  • Johnson and Johnson Services, Inc.
  • Cipla Inc.
  • Perrigo Company plc
  • Bausch Health Companies Inc.
  • Glenmark
  • NJOY
  • Juul Labs
  • Who should buy this report?

    The North America Smoking Cessation Aids Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Smoking Cessation Aids Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now